Abstract 1419P
Background
Brain metastases (BM) are a frequent complication in patients with non-small lung cancer (NSCLC). Treating BM is challenging as the blood-brain barrier can limit intracranial drug delivery. Data from different trials suggest that antibody-drug conjugates (ADC) can have clinically relevant intracranial activity. This study aims to characterize the gene expression of ADC targets in NSCLC-BM to guide treatment decisions.
Methods
Gene expression data from 125 BM resected from patients with NSCLC were obtained from 3 public datasets. Gene expression of 14 ADC targets (ERBB2, ERBB3, TACSTD2, MET, GPNMB, PTK7, MSLN, CD276, TF, AXL, EGFR, SLC34A2, CEACAM5 and ROR2) was evaluated to identify those consistently expressed across the cohorts. Additionally, hierarchical clustering was used to stratify NSCLC-BM, in each dataset separately, based on the combined relative gene expression of the common 25% most variable genes: MSLN, CEACAM5 and SLC34A2. Furthermore, association between clusters and clinical covariates was assessed for one of the datasets with available data (N=63).
Results
Gene expression evaluation showed that TACSTD2 (Trop-2) was ubiquitously highly expressed across datasets, suggesting that TACSTD2 could be a promising ADC target for NSCLC-BM. Contrarily, ROR2 showed consistently lower expression and would probably not be a good candidate in NSCLC-BM. Transcriptional patterns from the 3 most variable ADC targets (MSLN, CEACAM5, and SLC34A2) yielded common subgroups in all datasets defined by the following expression levels (respectively): High/High/High, Low/High/High, High/Low/Low. These groups did not correlate with clinical covariates.
Conclusions
Gene expression evaluation of ADC targets in NSCLC-BM resulted in the identification of TACSTD2 expression across all datasets. TACSTD2 might be a promising ADC target for patients with NSCLC with BM. Further validation is warranted in terms of protein expression. Our results underscore the potential value of gene expression profiling to identify new targets and improve patient selection in the context of NSCLC-BM ADC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Instituto de Salud Carlos III (CM22/00035).
Disclosure
E. Nadal: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Janssen, Pfizer, Merck Serono, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Sanofi, Qiagen, Janssen; Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Pfizer, Sanofi, AstraZeneca, Takeda, Amgen, Qiagen, Janssen; Financial Interests, Personal and Institutional, Funding, Clinical trial funded by Roche: Roche; Financial Interests, Personal and Institutional, Funding, BMS funded a clinical trial: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding, Merck Serono funded a clinical trial: Merck Serono; Non-Financial Interests, Advisory Role: Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20